^
    1d
    Acquired MYC rearrangement potentially associated with ibrutinib resistance in mantle cell lymphoma. (PubMed, Virchows Arch)
    In conclusion, our findings suggest that c-Myc overexpression and MYC rearrangement are associated with ibrutinib resistance in MCL. Detecting MYC rearrangement in selected MCL cases could be critical for optimizing treatment strategies and improving patient outcomes.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Imbruvica (ibrutinib)
    2d
    Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    2d
    Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy (clinicaltrials.gov)
    P2, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Aug 2026
    Enrollment open • Trial initiation date
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    3d
    Lineage-determining transcription factors constrain cohesin to drive multi-enhancer oncogene regulation. (PubMed, Nat Cell Biol)
    Mechanistically, we discovered that enhancer positioning at local topological centres is required for promoter engagement, with EBF1 acting as a permeable barrier to loop-extruding cohesin at enhancers. Extending these findings to T cell leukaemia, we show that lineage-determining transcription factors such as EBF1 and TCF1 radially position enhancers within gene loci to enable multi-enhancer regulation of key oncogenes at the single-allele level.
    Journal
    |
    EBF1 (EBF Transcription Factor 1)
    3d
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=34, Recruiting, Peking University Third Hospital
    New trial
    |
    Inokai (orelabrutinib) • pomalidomide • Anruixi (zuberitamab)
    7d
    Managing Treatment-Emergent Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CAR-T Cell Therapy: A Case-Based Review of the use of Emapalumab. (PubMed, Hematol Oncol)
    This paper presents a case of a 56-year-old woman with relapsed mantle cell lymphoma (MCL) treated with the CAR-T cell therapy, brexucabtagene autoleucel, who had subsequently developed CRS and later IEC-HS. Initial management included tocilizumab, corticosteroids, and anakinra, followed by the compassionate use of emapalumab, an interferon-γ blocker...Vigilant monitoring and tailored therapeutic approaches are required to effectively manage toxicities associated with CAR-T cell therapy, to maximize its benefits and minimize adverse effects. In more severe IEC-HS cases, emapalumab may be used as an effective targeted therapy.
    Review • Journal
    |
    IFNG (Interferon, gamma)
    |
    Tecartus (brexucabtagene autoleucel) • Actemra IV (tocilizumab) • Kineret (anakinra)
    9d
    Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Calquence (acalabrutinib) • CD19 CAR T cells
    9d
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)
    9d
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Nov 2025 | Trial primary completion date: Jun 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    10d
    This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=42, Recruiting, LTZ Therapeutics, Inc. | Initiation date: Sep 2025 --> Dec 2025
    Trial initiation date
    10d
    MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma. (PubMed, Blood Adv)
    Longitudinal cfDNA analysis in ALR revealed clonal evolution during response and progression. This safe and active regimen is feasible as a time-limited initial therapy for MCL patients and warrants further evaluation in response-adapted strategy.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    clonoSEQ
    |
    Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • Calquence (acalabrutinib)
    17d
    Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Completed --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    FLT3-ITD mutation • NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan • spanlecortemlocel (MGTA-456)